| Date | Title | Description |
| 25.05.2026 | Dr. Desirée Cox Joins Hemostemix Board of Directors | Dr. Desiree Cox joins Hemostemix Board of Directors
Hemostemix Inc. (TSX:HEM)
Hemostemix represents a compelling regenerative medicine, vascular biology, and patient-centered innovation. I look forward to supporting Hemostemix as it advance... |
| 21.05.2026 | Hemostemix $1,000,000 Private Placement | Hemostemix Inc. Announces $1,000,000 non brokered private placement of up to 20 Million Units at $0.05 each.
Hemostemix Inc. (OTCQB:HMTXF)CALGARY, ALBERTA, CANADA, May 21, 2026 /EINPresswire.com/ -- Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF... |
| 02.05.2023 | Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company | Calgary, Alberta--(Newsfile Corp. - May 2, 2023) - Hemostemix Inc. HEM HMTXF 2VF ("Hemostemix" or the "Company") is pleased to announce it has engaged Chris McNorgan, PhD, to drive a license agreement of NCP-01 with a co... |
| 23.01.2023 | InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01 | - |
| 04.02.2022 | Hemostemix : Announces Financing | Hemostemix Announces Financing February 2, 2022
February 2, 2022 Calgary, Alberta - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM; OTC: HMTXF) is pleased to announce a non-brokered private placement of up to... |
| 28.10.2021 | Hemostemix Confirms OTCQB Listing | Hemostemix Confirms OTCQB Listing October 28, 2021
October 28, 2021, Calgary, Alberta - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV:HEM; OTCQB:HMTXF; FSE:2VFO) is pleased to announce it is now up-listed to trad... |
| 19.10.2021 | Hemostemix : Confirms its OTCQB Application is Filed | Hemostemix Confirms its OTCQB Application is Filed October 19, 2021
October 19, 2021, Calgary, Alberta - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV:HEM; OTC:HMTXF; FSE:2VFO) is pleased to announce it filed wit... |
| 14.10.2021 | Hemostemix : Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer | Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer October 14, 2021
October 14, 2021, Calgary, Alberta - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV:HEM; OTC: HMTXF; FRA:2VFO) is ple... |
| 05.10.2021 | Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain | Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to no Chest Pain October 4, 2021
October 4, 2021, Calgary, Alberta - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM; OTC: HMTXF) is plea... |
| 05.10.2021 | Hemostemix : Announces Five Million Unit Private Placement | Hemostemix Announces Five Million Unit Private Placement October 4, 2021
September 8, 2021, Calgary, Alberta - Hemostemix Inc. ("Hemostemix" or the "Company") (TSXV: HEM; OTC: HMTXF) is pleased to announce a non-brokered... |
| 21.09.2021 | Hemostemix : Announces Closing of First Tranche of Unit Private Placement | Hemostemix Announces Closing of First Tranche of Unit Private Placement September 21, 2021
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
September 21, 2021, Calgary, Alberta - Hemostemix Inc. (&quo... |
| 14.09.2021 | Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years | Calgary, Alberta--(Newsfile Corp. - September 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the first of a series of video interviews with ACP-01 recipient-pa... |
| 08.09.2021 | Hemostemix Announces Five Million Unit Private Placement | Calgary, Alberta--(Newsfile Corp. - September 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement for gross proceeds of up to $1,250... |
| 06.07.2021 | Hemostemix Announces Warrant Repricing and Extension | Calgary, Alberta--(Newsfile Corp. - July 5, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce, subject to TSX Venture Exchange Approval, that it has ext... |
| 11.06.2021 | HEMOSTEMIX INC.
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture | Calgary, Alberta--(Newsfile Corp. - June 11, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it closed its previously announced $2,500,000 conver... |
| 31.05.2021 | HEMOSTEMIX INC.
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Ma... | Calgary, Alberta--(Newsfile Corp. - May 31, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE:2VF0) ("Hemostemix" or the "Company") reminds shareholders that due to COVID-19, its Annual and Special Meeting wil... |
| 30.05.2021 | HEMOSTEMIX INC.
Hemostemix : Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update | Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update May 29, 2021
Calgary, Alberta, May 29, 2021-Hemostemix Inc. ('Hemostemix' or the 'Compan... |
| 30.05.2021 | Hemostemix : Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update | Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update May 29, 2021
Calgary, Alberta, May 29, 2021-Hemostemix Inc. ('Hemostemix' or the 'Compan... |
| 29.05.2021 | HEMOSTEMIX INC.
Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Calgary, Alberta--(Newsfile Corp. - May 29, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Comp... |
| 07.05.2021 | HEMOSTEMIX INC.
Hemostemix Announces Warrant Repricing and Extension | Calgary, Alberta--(Newsfile Corp. - May 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has, subject to TSX Venture Exchange Approval, repr... |
| 06.05.2021 | Hemostemix : Announces Warrant Repricing and Extension | Hemostemix Announces Warrant Repricing and Extension May 6, 2021
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Calgary, Alberta, May 6, 2021-Hemostemix Inc. ('Hemostemix' or the 'Company') (TSXV: ... |
| 01.05.2021 | HEMOSTEMIX INC.
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis | Calgary, Alberta--(Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up completed in April... |
| 30.04.2021 | HEMOSTEMIX INC.
Hemostemix : Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis | Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis April 30, 2021
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSE... |
| 26.04.2021 | HEMOSTEMIX INC.
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering | Calgary, Alberta--(Newsfile Corp. - April 26, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Company") announces that, further to its April 9, 2021 news release announcing its... |
| 23.04.2021 | HEMOSTEMIX INC.
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list | Calgary, Alberta--(Newsfile Corp. - April 23, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO.F) ("Hemostemix" or the "Company") is pleased to announce the completion of the Phase II Clinical Trial subject ... |
| 10.04.2021 | HEMOSTEMIX INC.
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates | Calgary, Alberta--(Newsfile Corp. - April 9, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has secured a $2,500,000 lead order from a direct... |
| 08.04.2021 | HEMOSTEMIX INC.
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd. | Calgary, Alberta--(Newsfile Corp. - April 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0.F) ("Hemostemix" or the "Company") is pleased to announce it is trading on the Frankfurt Stock Exchange under symbo... |
| 30.01.2021 | HEMOSTEMIX : ANNOUNCES HS 12 – 01 CLINICAL TRIAL COMPLETION OF SUBJECTS' FOLLOW-UP VISITS AT THE END OF MARCH AND WARRANTS EXTENTED AND REPRICED | HEMOSTEMIX ANNOUNCES HS 12 - 01 CLINICAL TRIAL COMPLETION OF SUBJECTS' FOLLOW-UP VISITS AT THE END OF MARCH AND WARRANTS EXTENTED AND REPRICED January 28, 2021
Calgary, Alberta, January 28, 2021 - Hemostemix Inc. ('Hemostemix' or the 'Compa... |
